Bio
Dr. Jeysen Yogaratnam combines distinguished academics with private sector success across large pharma, biotechs, and start-ups, in multiple regions including the USA, Europe, and Asia. Dr. Yogaratnam earned his MBA from MIT (U.S.A), and Doctorate from University of Hull (U.K.), multiple Diplomas in Surgery in the U.K. a medical degree from The Royal College of Surgeons in Ireland (Dublin, Republic of Ireland) and was selected for a prestigious leadership development course through Johnson & Johnson (U.S.). Dr. Yogaratnam comes with 17+ of leadership experiences following roles at Bristol Myers Squibb, Vertex Pharmaceuticals, Johnson & Johnson, Aligos Therapeutics, Eiger Biopharmaceuticals and Drug Farm.
Dr. Yogaratnam's extensive drug development experience spans therapeutic areas such as infectious diseases (HIV, HCV, HBV, HDV), liver diseases (NASH, PBC), oncology, inflammatory diseases (RA), autoimmune diseases (ROSAH), rare diseases (HDV, ROSAH), chronic kidney disease, and cardiovascular conditions — enabling robust clinical insights across nearly any disease state. Dr. Yogaratnam is skilled in building out niche teams, dedicated business units, and transitioning entities into clinical-stage biotechs. Dr. Yogaratnam is highly skilled in executing comprehensive drug development programs, encompassing preclinical research, Chemistry Manufacturing and Control (CMC), regulatory submissions, and clinical trial management. He has a track record of leading multiple Phase 1, 2 and 3 clinical trials.
Dr. Yogaratnam has effectively managed multidisciplinary groups to achieve clinical and organizational goals. His ability to identify operational challenges, develop innovative solutions, and implement effective plans has driven the advancement of clinical programs and operational efficiency. Dr. Yogaratnam's extensive global experience has enabled him to cultivate a vast network of professional relationships which has been instrumental in advancing clinical programs and fostering high value collaborations. His deep expertise in clinical drug development and strategic execution, coupled with his ability to navigate diverse therapeutic areas, positions him as a versatile and impactful leader in the biopharmaceutical industry.